Shenzhen Chipscreen Biosciences Co., Ltd. (688321)

Overview

Shenzhen Chipscreen Biosciences Co., Ltd. is a pioneering biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs. Since its establishment in 2001, the company has been at the forefront of addressing complex human diseases across five main therapeutic areas: cancer, metabolic diseases, autoimmune disorders, central nervous system disorders, and antivirals. Headquartered in Shenzhen, China, Chipscreen Biosciences combines cutting-edge research with innovative drug development approaches, aiming to deliver novel treatments that improve patient outcomes.

Products and Services

• Chidamide

A selective benzamide inhibitor of histone deacetylase (HDAC) that particularly targets subtypes 1, 2, 3 of class I HDAC. Known for its potential in treating various types of cancer, Chidamide represents a new class of anticancer agents that modify the expression of key genes involved in cancer cell survival and proliferation.

• Chiglitazar

Identified as a next-generation insulin sensitizing drug candidate, Chiglitazar has been developed for the management of type 2 diabetes mellitus. It works by improving the body's sensitivity to insulin, thus offering a promising solution for patients struggling with this form of diabetes.

• Chiauranib

An innovative molecule inhibiting multiple targets, including aurora B/VEGFR/PDGFR/c-Kit/CSF1R, Chiauranib is designed to combat various forms of cancer through a multifaceted approach. By simultaneously blocking these critical pathways, Chiauranib aims to effectively halt tumor growth and reduce cancer cell proliferation.

• CS12192

A highly selective JAK3 kinase inhibitor, CS12192 focuses on treating autoimmune disorders. Through its targeted action, CS12192 is intended to modulate the immune system response, providing relief and therapeutic benefits to individuals living with autoimmune conditions.